Literature DB >> 10644076

Albendazole generics--a comparative in vitro study.

E Galia1, J Horton, J B Dressman.   

Abstract

PURPOSE: We sought to determine whether disintegration and dissolution behavior differs among various albendazole generic formulations obtained from third world countries and to compare them with the innovator's product.
METHODS: Dissolution behavior of various albendazole formulations was studied with USP Apparatus 2 in SGFsp and in a modified SGFsp which contained 0.1% of the nonionic surfactant Triton X 100. Disintegration was tested according to the European Pharmacopoeia.
RESULTS: Dissolution experiments in SGFsp showed a wide range in rate and extent of albendazole dissolution. The innovator product released 81 percent within two hours, a profile matched by only one other formulation. For other formulations 32 to 64% was released within two hours. Use of a modified SGFsp, containing 0.1% Triton X 100 to simulate the surface tension of gastric juice, resulted in less discrimination between products. The innovator product again showed the fastest and most complete dissolution, with ninety percent released within two hours. The generic formulations released between 67 and 82%, except for one formulation which achieved only 43% release. The results in SGFsp plus Triton X 100 may be more meaningful than in SGFsp since the surface tension of the medium is closer to the physiological value. All formulations passed the disintegration test according to the European Pharmacopoeia, with disintegration times ranging from 2.5 to 11 minutes.
CONCLUSIONS: Generic albendazole products vary widely in their dissolution behavior. Differences among products were greater in SGFsp than in SGFsp plus Triton X 100. These differences were not reflected in the disintegration behavior of the products.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10644076     DOI: 10.1023/a:1018907527253

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  5 in total

1.  Dissolution kinetics of drugs in human gastric juice--the role of surface tension.

Authors:  P Finholt; S Solvang
Journal:  J Pharm Sci       Date:  1968-08       Impact factor: 3.534

2.  Interdependence of physiological surfactant and drug particle size on the dissolution behavior of water insoluble drugs.

Authors:  S L Lin; J Menig; L Lachman
Journal:  J Pharm Sci       Date:  1968-12       Impact factor: 3.534

3.  Effect of tablet processing and formulation factors on dissolution rate of the active ingredient in human gastric juice.

Authors:  S Solvang; P Finholt
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

4.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

5.  Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs.

Authors:  E Galia; E Nicolaides; D Hörter; R Löbenberg; C Reppas; J B Dressman
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

  5 in total
  12 in total

1.  The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs.

Authors:  Mehran Yazdanian; Katherine Briggs; Corinne Jankovsky; Amale Hawi
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

Review 2.  The use of biorelevant dissolution media to forecast the in vivo performance of a drug.

Authors:  Sandra Klein
Journal:  AAPS J       Date:  2010-05-11       Impact factor: 4.009

3.  Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update.

Authors:  Ekarat Jantratid; Niels Janssen; Christos Reppas; Jennifer B Dressman
Journal:  Pharm Res       Date:  2008-04-11       Impact factor: 4.200

4.  Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs.

Authors:  S Gurunath; Baswaraj K Nanjwade; P A Patila
Journal:  Saudi Pharm J       Date:  2013-04-08       Impact factor: 4.330

5.  In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol and Gelucire 44/14.

Authors:  Sylvie Fernandez; Stéphanie Chevrier; Nicolas Ritter; Bruno Mahler; Frédéric Demarne; Frédéric Carrière; Vincent Jannin
Journal:  Pharm Res       Date:  2009-05-19       Impact factor: 4.200

6.  Comparative study of the quality and efficacy of originator and generic albendazole for mass treatment of soil-transmitted nematode infections in Nepal.

Authors:  Marco Albonico; Pragya Mathema; Antonio Montresor; Balkrishna Khakurel; Valerio Reggi; Sharada Pandey; Lorenzo Savioli
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-11-28       Impact factor: 2.184

7.  Miniaturized assay for solubility and residual solid screening (SORESOS) in early drug development.

Authors:  Nicole Wyttenbach; Jochem Alsenz; Olaf Grassmann
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580

8.  Estimation of intragastric solubility of drugs: in what medium?

Authors:  Maria Vertzoni; Eleni Pastelli; Dimitris Psachoulias; Lida Kalantzi; Christos Reppas
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580

9.  Assessment of Efficacy and Quality of Two Albendazole Brands Commonly Used against Soil-Transmitted Helminth Infections in School Children in Jimma Town, Ethiopia.

Authors:  Sileshi Belew; Mestawet Getachew; Sultan Suleman; Tesfaye Mohammed; Habetewold Deti; Matthias D'Hondt; Evelien Wynendaele; Zeleke Mekonnen; Jozef Vercruysse; Luc Duchateau; Bart De Spiegeleer; Bruno Levecke
Journal:  PLoS Negl Trop Dis       Date:  2015-09-25

10.  Comparative dissolution study on counterfeit medicines of PDE-5 inhibitors.

Authors:  E Deconinck; S Andriessens; J L Bothy; P Courselle; J O De Beer
Journal:  J Pharm Anal       Date:  2014-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.